Proton-Transfer Dynamics Regulates CO Electroreduction Products via Hydrogen Coverage.

Electrochemical conversion of CO to hydrocarbons is a promising approach to carbon neutrality and energy storage. The formation of reaction intermediates involves crucial steps of proton transfer, making it essential to understand the role of protons in the electrochemical process to control the product selectivity and elucidate the underlying catalytic reaction mechanism of the CO electrochemical reduction (CORR). In this work, we proposed a strategy to regulate product selectivities by tuning local proton transport rates through a surface resin layer over cuprous oxides.

Depressive symptoms after surgical and medical management of OSA: a systematic review and meta-analysis.

Purpose: To evaluate the effect of CPAP and surgical alternatives for OSA on depression and compare the results of surgery to CPAP. ​METHODS: COCHRANE Library, CINAHL, PubMed, and Scopus databases were searched for English-language articles. Meta-analysis of continuous measures (mean), proportions (%), and mean difference (Δ) with 95% confidence interval was conducted for objective and subjective outcomes before and after treatment with CPAP or surgical interventions.

Injury prevention in youth football (soccer): a comprehensive description of the development process of the 'FUNBALL' programme.

Many football injury prevention programmes (IPPs) have been developed to target various injuries and populations. There was no specific IPP for youth players in place before. However, several existing IPPs designed for adults were also assessed in the youth population.

Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Background & Aims: The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we aim to uncover the underlying cellular processes driving clinical benefit versus resistance to atezo+bev.

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Objective: To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression.

Methods: For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with psychological support.